Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing cell and gene therapies for life-threatening diseases. Co.'s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). Co.'s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The ABEO stock yearly return is shown above.
The yearly return on the ABEO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2025 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABEO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|